Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 357

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 357
---
 develop innovative genomic services, and potentially integrate the omni -modaldata with complex analytics to accelerate our innovation. To deliver our services, we process blood, tissue, microbiome and saliva samples from our own sales channels and partners. According to the public report titled “Predictive Genetic Testing and Consumer Genomics Market Research 2024 -2034”, published by Erevna Healthcare on Research and Markets, dated January23, 2025, a significant increase in interest in genetics among both consumers and healthcare professionals is expected, as the market adoption of genetic tests has experienced significant growth globally, driven by increased emphasis on early disease detection, personalized medicine, and genetics in addressing health conditions. An industry public report titled “Latin America Precision Medicine Market Size & Outlook”, published by Horizon Grand View Research during 2023 estimates that the Latin American genomics market will be valued at approximately $6.15 billion by 2030, growing at a compound annual growth rate (CAGR) of 11.3% per year. This growth reflects the rising prevalence of genetic and rare disorders and the expanding use of genetic testing in fields such as oncology, where personalized approaches are increasingly critical. Additionally, these market and industry public reports highlight that consumer demand for genetic testing continues to rise, further expanding the market and indicating a growing awareness of and interest in genetic health insights among 176 the public. Advances in sequencing technology and rising awareness and demand for genetic testing support this growth. Further, according to a public report titled “The Cost of Sequencing a Human Genome”, published by the National Human Genome Research Institute, dated November1, 2021, technological advances have reduced the costs of genetic sequencing, increasing their accessibility. To boost market adoption, we expect to launch the consortium to offer our partners exclusive genomic services with competitive pricing, quick result turnaround times, pre- and post -testsupport, and market development initiatives. This consortium will be launched in a phased approach, as we build relationships, assess local market needs, and locate the results from our offerings to ensure a strong market fit. Our expertise in delivering precise, personalized results and developing innovative products, some of which are suitable for in -homeuse, is fundamental to our operations. We utilize both dry and wet labs, including laboratories from strategic partners as part of a hybrid operational model, and integrate multi -modaldata, allowing us to cater to the needs of patients, users, insurance companies, pharma, and other health stakeholders within the specific markets where we offer our services. Currently, our products are